PK/PD Biomarker Analysis to Assess Tumor-Specific Enrichment and Payload Delivery of ACTM-838, a Microbial-Based Immunotherapy VIEW POSTER PDF
The session — “FDA’s START Pilot Program in Action: Insights from Year One”—will spotlight Myrtelle’s experience in this bold regulatory initiative designed to fast-track therapies for rare and life-threatening diseases.
The session — “FDA’s START Pilot Program in Action: Insights from Year One”—will spotlight Myrtelle’s experience in this bold regulatory initiative designed to fast-track therapies for rare and life-threatening diseases.